Valuation : Adaptive Biotechnologies Corporation

Market Cap 3.88B 3.35B 3.15B 2.87B 5.4B 369B 5.43B 37.26B 14.5B 188B 14.58B 14.27B 622B P/E 2026 *
-44.7x
P/E 2027 * -138x
Enterprise Value 3.83B 3.3B 3.1B 2.83B 5.32B 363B 5.35B 36.7B 14.28B 185B 14.36B 14.05B 612B EV / Sales 2026 *
13x
EV / Sales 2027 * 10.5x
Free-Float
97.93%
Yield 2026 *
-
Yield 2027 * -
1 day-2.33%
1 week-7.28%
Current month-2.33%
1 month+7.84%
3 months+59.82%
6 months+51.94%
Current year+49.88%
1 week 23.86
Extreme 23.865
26.87
1 month 21.83
Extreme 21.829
26.87
Current year 12
Extreme 12
26.87
1 year 12
Extreme 12
26.87
3 years 2.28
Extreme 2.28
26.87
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 A Sell

Director

-9,615 0.0060%
8/18/26 A Exercice

Director

60,664 0.0379%
8/18/26 A Exercice

Chief Executive Officer

836,028 0.5224%
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-7.28%+84.67%+257.42% 3.88B
+1.35%-1.90%+271.30%+34.63% 3.75B
+0.56%-1.39%+43.14%+62.66% 3.49B
-2.27%-3.60%+258.49%+403.29% 2.53B
-0.44%-4.84%-28.21%-28.01% 2.21B
+3.11%+9.01%+44.15% - 1.64B
-4.45%-18.89%+201.65%-29.13% 1.09B
-1.79%+4.93%+29.16%+49.32% 1.1B
-0.97%-6.23%+24.88%+68.14% 642M
+0.43%-3.15%-34.90%-3.53% 537M
Average -0.68%-3.66%+89.43%+90.53% 2.09B
Weighted average by Cap. -0.52%-3.37%+115.49%+123.36%

Financials

2026 *2027 *
Net sales 293M 253M 238M 217M 408M 27.83B 410M 2.81B 1.09B 14.16B 1.1B 1.08B 46.94B 359M 309M 291M 265M 498M 34.03B 501M 3.44B 1.34B 17.31B 1.35B 1.32B 57.39B
Net income -85.78M -73.99M -69.6M -63.41M -119M -8.14B -120M -823M -320M -4.14B -322M -315M -13.73B -27.55M -23.77M -22.36M -20.37M -38.3M -2.61B -38.51M -264M -103M -1.33B -103M -101M -4.41B
Net Debt -58.99M -50.89M -47.87M -43.61M -82.01M -5.6B -82.45M -566M -220M -2.85B -221M -217M -9.44B -104M -89.57M -84.25M -76.75M -144M -9.85B -145M -996M -388M -5.01B -390M -381M -16.62B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
01/09/26 $24.34 -2.33% 1,621,010
31/08/26 $24.92 -1.07% 2,237,634
28/08/26 $25.19 -4.73% 1,509,096
27/08/26 $26.44 +1.07% 1,944,721
26/08/26 $26.16 -0.34% 1,387,277
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.34USD
Average target price
25.07USD
Spread / Average Target
+3.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock